regenicin page header biomedical collagen polymer header

Regenicin, Inc., is a biotechnology company specializing in the development
of regenerative cell therapies to restore the health of damaged tissues and organs.


Regenicin is playing a critical role in the development of the therapeutic candidate, NovaDerm™, a cultured cell technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.

show stock information

March -3-2015: Regenicin (RGIN) Receives $2.3 Million in
Final Payment from Amarantus

Company values the sale from the Asset Purchase Agreement at $8.023 million.

Nov-18-2014: Regenicin Enters Asset Purchase Agreement
Regenicin Enters Agreement with Amarantus
 click links for more information